Quick Take
NLS Pharmaceutics (NLSP) has filed to raise $40.25 million in an IPO of its common stock, according to an F-1 registration statement.
The company is advancing a pipeline of drug candidates for the treatment of various central nervous system disorders.
NLSP expects to begin pivotal trials for its lead candidate in late 2020.
When we learn more about the IPO’s details, I’ll provide a final opinion.
Company & Technology
Stans, Switzerland-based NLS was founded to develop treatments for central nervous system disorders.The firm's current area of focus is developing single